



PRESS RELEASE

Sosei Heptares publishes 30th Anniversary Commemorative Booklet

Tokyo, Japan and Cambridge, UK, 15 September 2020 – Sosei Heptares is delighted to announce the publication of a 30th Anniversary Commemorative Booklet to accompany the celebration of the 30th anniversary of the Group’s founding in June 2020.

This commemorative booklet provides an overview of the history of Sosei Heptares from its founding in 1990 up until the present day. The booklet is divided into three 10-year periods, starting with “The Founding Years (1990-2000),” followed by “Building the Foundation for Success (2000-2010)” and “Accelerating Growth on an International Stage (2010-2020).” In addition, the booklet contains perspectives from a number of people connected with the Group, who provide their perspectives on key moments in its evolution over the years and its exciting potential for future growth. As Sosei Heptares looks forward to a new era in its history, it hopes that this booklet will provide an insightful and interesting roadmap, highlighting the growth and development of a leading international biopharmaceutical company anchored in Japan.

To view the 30th Anniversary Commemorative Booklet, please visit [here](#).

– ENDS –

About Sosei Heptares

We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s leading pharmaceutical companies, including AbbVie, AstraZeneca, Genentech (Roche), Novartis, Pfizer and Takeda and additionally with multiple emerging technology companies. Sosei Heptares is headquartered in Tokyo, Japan with corporate offices and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.

For more information, please visit <https://www.soseiheptares.com/>
LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)



PRESS RELEASE

Enquiries:

Sosei Heptares

Shinichiro Nishishita – VP Investor Relations, Head of Regulatory Disclosures

+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Candelle Chong – VP Corporate Strategy and Communications

+44 (0)1223 949 392 | Comms@SoseiHeptares.com

Citigate Dewe Rogerson

Yas Fukuda – Japanese Media

+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com

Mark Swallow, David Dible – International Media

+44 (0)20 7638 9571 | SoseiHeptares@citigatedewerogerson.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.